Material Transfer Agreements (MTA): The Practical Process for Sharing Research Materials

A Material Transfer Agreement (MTA) is the contract that has to be in place before tangible research materials — a cell line, a plasmid, an antibody, a reagent, an animal model, a tissue sample — move between institutions. CASRAI’s dictionary entry covers the operational definition; this guide covers the practical process: which template applies, who actually negotiates and signs it, where negotiations typically get stuck, and roughly how long it takes.

This guide focuses on US practice, where the Uniform Biological Material Transfer Agreement (UBMTA) and the NIH Simple Letter Agreement are the dominant standard instruments. Institutions outside the US generally use equivalent bespoke or national templates; the negotiation issues below (IP, publication rights, indemnification, compliance overlays) apply regardless of jurisdiction even where the specific template doesn’t.

What triggers an MTA

An MTA is needed whenever tangible research property is shipped or received across an institutional boundary and the recipient intends to use it for their own research — not when data or a document changes hands (that’s a Data Sharing Agreement or Data Use Agreement instead) and not for routine catalogue purchases of a commercially available reagent under standard terms. Internal transfers between labs of the same legal institutional entity typically don’t need an MTA either, though biosafety registration can still apply. See the MTA dictionary entry for the full operational definition, worked examples, and counter-examples.

MTAs are executed at the institutional level, not by the individual researcher — the same signing pattern used for DSAs and DUAs. A principal investigator identifies the need and initiates the request, but the institution — not the PI — is the contracting party and bears the resulting obligations.

Standard US templates: UBMTA and the NIH Simple Letter Agreement

Most academic-to-academic biological material transfers in the US don’t require a bespoke contract at all, because a standardized template already exists:

• Uniform Biological Material Transfer Agreement (UBMTA). Published in final form by NIH in the Federal Register on March 8, 1995, the UBMTA is a standardized master agreement that non-profit institutions sign once with the AUTM-administered UBMTA Master Agreement repository, then use for individual transfers via a short Implementing Letter rather than renegotiating full terms every time. Hundreds of US research institutions are signatories. The two-step structure — one master agreement, then a one-page letter per transfer — is what makes routine academic material sharing fast rather than a fresh negotiation each time.
• NIH Simple Letter Agreement. For transfers that don’t involve a patent, a pending patent application, or material likely to be commercially licensed, the UBMTA framework provides an even lighter-weight Simple Letter Agreement instead of the Implementing Letter — appropriate for routine, non-proprietary academic exchanges.

Non-standard MTAs — transfers involving industry partners, patented material, or material the provider intends to commercialize — fall outside this streamlined path and require individual negotiation, typically led by the institution’s technology-transfer or research-contracts office rather than handled directly by the researchers involved.

Who’s involved, and what the process actually looks like

1. The PI identifies the need — usually while planning a collaboration or after being offered material by another lab — and submits a request to their institution’s technology transfer office (TTO), sponsored programs office, or research contracts office.
2. The office classifies the transfer. If both institutions are UBMTA signatories and the material isn’t patented or commercially sensitive, the office issues or countersigns a one-page Implementing Letter or Simple Letter Agreement — often the fastest path.
3. If it’s a non-standard MTA (an industry provider’s own template, or material with IP attached), the office negotiates the substantive terms — see the sticking points below — against the institution’s standard positions.
4. Compliance reviews run in parallel where applicable: an Institutional Biosafety Committee review for biohazardous material, and an export-control screening (below) before anything ships.
5. The institution — not the PI — signs, binding the institution as the contracting party.

Because this process is institutional rather than researcher-to-researcher, the office handling it is usually the same one — or works closely with the same one — that negotiates data sharing agreements and reviews confidentiality agreements, and coordinates with the IRB where the material is linked to human-subjects research (for example, human tissue samples tied to an active protocol).

Where negotiations actually get stuck

For material that falls outside the standard UBMTA/Simple Letter path, a small set of clauses accounts for most of the delay:

• Modifications and derivatives (“progeny”). Who owns anything the recipient creates using the original material — a modified cell line, a new antibody derived from it, offspring of an animal model. Providers commonly retain rights over unmodified material and its direct progeny while recipients retain rights over genuinely new inventions made using it; where that line falls is negotiated, not assumed.
• Reach-through rights. Some commercial providers request an option or license on future discoveries the recipient makes using the material, extending well beyond the material itself. This is one of the more contentious terms in non-standard MTAs and a common reason a negotiation stalls, because it can constrain the recipient’s ability to publish or license unrelated future work.
• Publication rights and review delay. Providers frequently request a pre-publication review window. A combined review-plus-delay period of 30–60 days is a common range in practice at research institutions, with some institutional policies capping the total combined period (initial review plus any additional delay to allow patent filing) at 90 days. Terms vary by institution and by provider, so this is a negotiated ceiling, not a universal rule.
• Indemnification and liability. Providers often want the recipient to indemnify them against harm arising from use of the material; recipient institutions typically resist open-ended indemnification and negotiate it down to their own negligence or misuse, consistent with normal institutional risk positions.
• Onward transfer. Whether the recipient may pass the material to a third party (a collaborator, a core facility, a company) without the original provider’s consent — routinely restricted by default in both UBMTA and non-standard MTAs.

Compliance overlays: export control and biosafety

Two compliance reviews commonly run alongside — not instead of — the contractual negotiation, and can independently determine timeline:

• Export control. Biological materials, associated technical data, and in rare cases certain organisms or toxins can be subject to the Export Administration Regulations (EAR), administered by the US Department of Commerce’s Bureau of Industry and Security, and less commonly the International Traffic in Arms Regulations (ITAR) for defense-related items. Shipping material to a recipient outside the US, or even hosting a foreign national researcher who will handle controlled material domestically (“deemed export“), can require classification and, in some cases, a license before the transfer proceeds. Institutions typically route this through a dedicated export control office working alongside the TTO.
• Biosafety review. Materials involving biohazardous agents, recombinant material, or (in the US) CDC/USDA-listed select agents require Institutional Biosafety Committee (IBC) review and containment-level determination before shipment or receipt, independent of whether the MTA itself is a standard UBMTA transaction or a negotiated one.

Realistic timelines

Timelines vary widely by institution and material type, but a rough pattern holds across research-administration practice: a standard UBMTA Implementing Letter or Simple Letter Agreement between two signatory academic institutions, with no compliance flags, is often the fastest path — commonly turned around in days to a few weeks once the request reaches the TTO. A non-standard MTA — an industry provider’s own template, patented material, or a first-time negotiation over reach-through rights or indemnification — routinely takes several weeks to a few months, and can extend well beyond that if the parties don’t converge on IP or liability terms. Building in lead time before a collaboration’s planned start date is standard advice from every technology-transfer office that publishes public guidance on the process — treat “we need the material next week” as the exception the process wasn’t designed for, not the default case to plan around.

MTA vs. related agreement types

MTAs are frequently confused with adjacent instruments that share the same institutional signing pattern but govern different things:

• Material Transfer Agreement (MTA) — governs tangible research materials: biological specimens, cell lines, reagents, physical samples. Not data.
• Data Sharing Agreement (DSA) — governs bidirectional or multilateral exchange of data between institutions. See CASRAI’s guide to data sharing agreements for what one typically contains and how it differs from an MTA in practice.
• Data Use Agreement (DUA) — governs one-directional access to a restricted or identifiable dataset from a single source.
• Confidentiality Agreement (NDA) — covers confidential information generally, without the material-specific terms (progeny, modifications, biosafety) an MTA requires; sometimes used alongside an MTA, not instead of one, when unpublished methods accompany the material.

If a collaboration involves both a physical shipment and an accompanying dataset, both an MTA and a DSA or DUA are usually needed — one instrument doesn’t substitute for the other.

Frequently asked questions

Who signs a material transfer agreement — the researcher or the institution?

The institution, not the individual researcher. A PI typically identifies the need and initiates the request, but the agreement is negotiated and executed by the institution’s technology-transfer, sponsored-programs, or research-contracts office, binding the institution as the contracting party — the same pattern used for data sharing agreements and data use agreements.

How long does it take to get a material transfer agreement in place?

It depends heavily on whether a standard template applies. A UBMTA Implementing Letter or Simple Letter Agreement between two signatory institutions, with no export-control or biosafety flags, is typically the fastest option. A non-standard MTA — an industry template, patented material, or a negotiation over reach-through rights, publication delay, or indemnification — commonly takes several weeks to a few months. Start the request well before the material is actually needed.

Do I need an MTA for a routine reagent purchase?

Generally no. Purchase of a commercially available reagent under a supplier’s standard catalogue terms doesn’t require an MTA. An MTA becomes necessary when material is transferred between research institutions for the recipient’s own research use, typically with restrictions on further use, modification, or onward transfer attached.

What’s the difference between an MTA and a data sharing agreement?

An MTA governs tangible research materials — cell lines, reagents, biological specimens. A Data Sharing Agreement governs data. If a collaboration involves shipping physical material alongside a dataset, both agreements are typically needed; neither substitutes for the other.

What is the UBMTA, and do all institutions use it?

The Uniform Biological Material Transfer Agreement is a standardized master agreement, finalized by NIH in 1995 and administered through AUTM, that lets signatory non-profit institutions transfer biological materials among themselves using a short Implementing Letter or Simple Letter Agreement instead of negotiating full terms for every transfer. Most major US research universities are signatories, but not all institutions are, and the UBMTA doesn’t apply to transfers involving a commercial partner, patented material, or material outside its biological-materials scope — those still need a negotiated, non-standard MTA.

Can the material provider restrict when I publish?

Often, yes, within limits that vary by institution. A pre-publication review period is a common MTA term — ranges of roughly 30 to 60 days appear frequently in institutional policy, sometimes with an additional delay allowed to permit a patent filing, and many institutions cap the combined review-plus-delay period. The specific number is negotiated per agreement and per institution’s standard position, not fixed by any single external standard.

For the broader research-integrity and compliance landscape this fits into, see CASRAI’s Research Integrity & Compliance cluster hub.